# Diagnostic Criteria for Myeloproliferative Neoplasms (MPN)

## Summary Table

### **1. Chronic Myeloid Leukemia (CML)**

- **Accelerated Phase (AP):**
  - **Bone marrow or peripheral blood blasts:** 10%-19%
  - **Peripheral blood basophils:** ≥ 20%
  - **Presence of additional clonal cytogenetic abnormality in Ph+ cells (ACA):** Consideration of lymphoblastic crisis if morphologically apparent lymphoblasts > 5%
- **Blast Phase (BP):**
  - **Bone marrow or peripheral blood blasts:** ≥ 20%
  - **Myeloid sarcoma:** Present
  - **Presence of morphologically apparent lymphoblasts (>5%):** Consideration of lymphoblastic crisis

### **2. Polycythemia Vera (PV)**

- **Major Criteria:**
  - Elevated hemoglobin or hematocrit
  - Presence of JAK2 V617F or JAK2 exon 12 mutation
  - Bone marrow biopsy showing age-adjusted hypercellularity with prominent erythroid, granulocytic, and increase in mature megakaryocytes without atypia
- **Minor Criterion:**
  - Subnormal serum erythropoietin level
- **Diagnosis:** Requires all 3 major criteria or the first 2 major criteria plus the minor criterion

### **3. Essential Thrombocythemia (ET)**

- **Major Criteria:**
  - Platelet count ≥ 450 × 10^9/L
  - Bone marrow biopsy showing proliferation mainly of the megakaryocytic lineage with increased numbers of enlarged, mature megakaryocytes with hyperlobulated staghorn-like nuclei, no significant increase or left shift in neutrophil granulopoiesis or erythropoiesis, no relevant BM fibrosis
  - Diagnostic criteria for BCR::ABL1-positive CML, PV, PMF, or other myeloid neoplasms are not met
  - Presence of JAK2, CALR, or MPL mutation
- **Minor Criteria:**
  - Presence of a clonal marker or absence of evidence of reactive thrombocytosis
- **Diagnosis:** Requires all major criteria or the first 3 major criteria plus the minor criteria

### **4. Primary Myelofibrosis (PMF)**

- **Early/Prefibrotic Stage (pre-PMF):**
  - **Major Criteria:**
    - Bone marrow biopsy showing megakaryocytic proliferation and atypia, bone marrow fibrosis grade < 2, increased age-adjusted BM cellularity, granulocytic proliferation, and often decreased erythropoiesis
    - Presence of JAK2, CALR, or MPL mutation or another clonal marker
    - Diagnostic criteria for BCR::ABL1-positive CML, PV, ET, myelodysplastic syndromes, or other myeloid neoplasms are not met
  - **Minor Criteria:**
    - Anemia not attributed to a comorbid condition
    - Leukocytosis ≥ 11 × 10^9/L
    - Palpable splenomegaly
    - Lactate dehydrogenase level above the reference range
- **Overt Fibrotic Stage:**
  - **Major Criteria:**
    - Bone marrow biopsy showing megakaryocytic proliferation and atypia, bone marrow fibrosis grade 2 or 3
    - Presence of JAK2, CALR, or MPL mutation or another clonal marker
    - Diagnostic criteria for ET, PV, BCR::ABL1-positive CML, myelodysplastic syndrome, or other myeloid neoplasms are not met
  - **Minor Criteria:**
    - Anemia not attributed to a comorbid condition
    - Leukocytosis ≥ 11 × 10^9/L
    - Palpable splenomegaly
    - Lactate dehydrogenase level above the reference range
    - Leukoerythroblastosis

### **5. Chronic Neutrophilic Leukemia (CNL)**

- **Diagnostic Criteria:**
  - **Peripheral blood white blood cell count:** ≥ 13 × 10^9/L
  - **Bone marrow:** Hypercellular with neutrophil granulocytes increased in percentage and absolute number, showing normal maturation
  - **CSF3R T618I or other activating CSF3R mutation:** Present
  - **Absence of diagnostic criteria for BCR::ABL1-positive CML, PV, ET, PMF, or myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions**

### **6. Chronic Eosinophilic Leukemia, Not Otherwise Specified (CEL, NOS)**

- **Diagnostic Criteria:**
  - **Peripheral blood hyper eosinophilia:** Eosinophil count ≥ 1.5 × 10^9/L and eosinophils ≥ 10% of white blood cells
  - **Blasts in peripheral blood and bone marrow:** ≤ 20%, not meeting other diagnostic criteria for AML
  - **No tyrosine kinase gene fusion:** Including BCR::ABL1, PDGFR, FGFR1, JAK2, or FLT3 fusions
  - **Bone marrow:** Shows increased cellularity with dysplastic megakaryocytes and often significant fibrosis, associated with an eosinophilic infiltrate or increased blasts ≥ 5% in the bone marrow and/or ≥ 2% in the peripheral blood
  - **Demonstration of a clonal cytogenetic abnormality and/or somatic mutation**

### **7. Idiopathic Hypereosinophilic Syndrome (iHES)**

- **Diagnostic Criteria:**
  - **Persistent peripheral blood hyper eosinophilia:** Eosinophil count ≥ 1.5 × 10^9/L and ≥ 10% eosinophils
  - **Organ damage and/or dysfunction:** Attributable to tissue hypereosinophilia
  - **No evidence of a reactive, well-defined autoimmune disease or neoplastic condition:** Underlying the hypereosinophilia
  - **Exclusion of lymphocyte variant hypereosinophilic syndrome**
  - **Bone marrow morphology:** Within normal limits except for increased eosinophils
  - **No molecular genetic clonal abnormality:** With the caveat of clonal hematopoiesis of indeterminate potential (CHIP)

### **8. Myeloproliferative Neoplasm, Unclassifiable (MPN-U)**

- **Diagnostic Criteria:**
  - **Clinical and hematological features:** Present
  - **Presence of JAK2, CALR, or MPL mutation or another clonal marker**
  - **Not meeting diagnostic criteria for other MPN, MDS, MDS/MPN, or BCR::ABL1-positive CML**

### **9. Myeloid Neoplasms with Eosinophilia and Tyrosine Kinase (TK) Gene Fusions**

- **Diagnostic Criteria:**
  - **Myeloid/lymphoid neoplasm with PDGFR, FGFR, JAK2, or FLT3 rearrangement**
  - **Presence of a specific TK gene fusion:** Such as PDGFR, FGFR, JAK2, or FLT3

### **10. Myeloid Neoplasms with TP53 Mutation**

- **Diagnostic Criteria:**
  - **Presence of TP53 mutation:** Confirmed by molecular analysis
  - **Clinical and hematological features:** Consistent with myeloid neoplasm

### **11. Myeloid Neoplasms Associated with Germline Predisposition**

- **Diagnostic Criteria:**
  - **Presence of a germline mutation predisposing to myeloid neoplasms:** Such as Noonan syndrome, Fanconi anemia, or other hereditary predisposition syndromes
  - **Clinical and hematological features:** Consistent with myeloid neoplasm

---

## Medical Decision Tree (MDT) for Diagnosis and Subtyping of Myeloproliferative Neoplasms (MPN)

### **Step 1: Initial Clinical and Laboratory Assessment**

1. **Complete Blood Count (CBC):**
   - Check for:
     - **Elevated platelets:** ≥ 450 × 10^9/L (ET, PMF, PV)
     - **Elevated hemoglobin/hematocrit:** > 16.5 g/dL in men, > 16.0 g/dL in women (PV)
     - **Elevated white blood cells:** ≥ 13 × 10^9/L (CNL)
     - **Elevated eosinophils:** ≥ 1.5 × 10^9/L (CEL, NOS)
     - **Presence of blasts:** ≤ 20% in peripheral blood and bone marrow (CEL, NOS)
2. **Bone Marrow Biopsy and Cytogenetics:**
   - Assess for:
     - **Megakaryocytic atypia:** (ET, PMF, PV)
     - **Neutrophil granulocytic proliferation:** (CNL)
     - **Eosinophilic infiltrate:** (CEL, NOS)
     - **Fibrosis:** (PMF)
     - **Clonal cytogenetic abnormalities:** (CEL, NOS, iHES)
     - **Molecular mutations:** JAK2 V617F, CALR, MPL, CSF3R, TP53

### **Step 2: Molecular Analysis**

1. **JAK2 V617F and Exon 12 Mutations:**
   - Confirm in:
     - **PV:** Essential for diagnosis
     - **ET, PMF:** Supporting evidence
2. **CALR and MPL Mutations:**
   - Confirm in:
     - **ET, PMF:** Essential for diagnosis
3. **CSF3R T618I Mutation:**
   - Confirm in:
     - **CNL:** Essential for diagnosis
4. **TP53 Mutation:**
   - Confirm in:
     - **Myeloid neoplasms with TP53 mutation:** Essential for diagnosis
5. **Germline Mutations:**
   - Confirm in:
     - **Myeloid neoplasms associated with germline predisposition:** Essential for diagnosis

### **Step 3: Subtype-Specific Diagnostics**

1. **Chronic Myeloid Leukemia (CML):**
   - **Accelerated Phase (AP):**
     - **Blasts:** 10%-19% in bone marrow or peripheral blood
     - **Basophils:** ≥ 20% in peripheral blood
     - **Additional cytogenetic abnormalities:** In Ph+ cells
   - **Blast Phase (BP):**
     - **Blasts:** ≥ 20% in bone marrow or peripheral blood
     - **Myeloid sarcoma:** Present
     - **Lymphoblastic crisis:** Consideration if morphologically apparent lymphoblasts > 5%
2. **Polycythemia Vera (PV):**
   - **Hematologic criteria:** Elevated hemoglobin/hematocrit
   - **Molecular criteria:** JAK2 V617F or JAK2 exon 12 mutation
   - **Bone marrow features:** Age-adjusted hypercellularity with prominent erythroid, granulocytic, and mature megakaryocytes without atypia
3. **Essential Thrombocythemia (ET):**
   - **Platelet count:** ≥ 450 × 10^9/L
   - **Bone marrow features:** Megakaryocytic proliferation with hyperlobulated staghorn-like nuclei, no significant increase or left shift in neutrophil granulopoiesis or erythropoiesis, no relevant BM fibrosis
   - **Molecular criteria:** JAK2, CALR, or MPL mutation
4. **Primary Myelofibrosis (PMF):**
   - **Early/Prefibrotic Stage:**
     - **Bone marrow features:** Megakaryocytic proliferation and atypia, bone marrow fibrosis grade < 2
     - **Molecular criteria:** JAK2, CALR, or MPL mutation
   - **Overt Fibrotic Stage:**
     - **Bone marrow features:** Megakaryocytic proliferation and atypia, bone marrow fibrosis grade 2 or 3
     - **Molecular criteria:** JAK2, CALR, or MPL mutation
5. **Chronic Neutrophilic Leukemia (CNL):**
   - **Bone marrow features:** Hypercellular with neutrophil granulocytes increased in percentage and absolute number, showing normal maturation
   - **CSF3R T618I mutation:** Present
6. **Chronic Eosinophilic Leukemia, Not Otherwise Specified (CEL, NOS):**
   - **Peripheral blood:** Eosinophil count ≥ 1.5 × 10^9/L and eosinophils ≥ 10% of white blood cells
   - **Bone marrow:** Increased cellularity with dysplastic megakaryocytes, significant fibrosis, and eosinophilic infiltrate or increased blasts
   - **Clonal cytogenetic abnormality or somatic mutation:** Present
7. **Idiopathic Hypereosinophilic Syndrome (iHES):**
   - **Persistent peripheral blood hyper eosinophilia:** Eosinophil count ≥ 1.5 × 10^9/L and ≥ 10% eosinophils
   - **Organ damage and/or dysfunction:** Attributable to tissue hypereosinophilia
   - **Exclusion of lymphocyte variant hypereosinophilic syndrome**
8. **Myeloproliferative Neoplasm, Unclassifiable (MPN-U):**
   - **Clinical and hematological features:** Present
   - **Molecular criteria:** JAK2, CALR, or MPL mutation or another clonal marker
   - **Not meeting diagnostic criteria for other MPN, MDS, MDS/MPN, or BCR::ABL1-positive CML**
9. **Myeloid Neoplasms with Eosinophilia and Tyrosine Kinase (TK) Gene Fusions:**
   - **Presence of specific TK gene fusion:** Such as PDGFR, FGFR, JAK2, or FLT3
10. **Myeloid Neoplasms with TP53 Mutation:**
    - **Presence of TP53 mutation:** Confirmed by molecular analysis
11. **Myeloid Neoplasms Associated with Germline Predisposition:**
    - **Presence of germline mutation predisposing to myeloid neoplasms:** Such as Noonan syndrome, Fanconi anemia

### **Step 4: Final Diagnosis and Subtyping**

- **Review all clinical, laboratory, molecular, and morphological findings** to assign the most accurate diagnosis and subtype.
- **Consider the presence of overlapping features** and apply the most specific diagnostic criteria for each subtype.

This MDT ensures a systematic and comprehensive approach to diagnosing and subtyping MPNs, incorporating all relevant diagnostic criteria and molecular findings.